Sagimet Biosciences Inc. SGMT
9.08 USD -0.54 (-5.61%)
Regular-session close
9.07 -0.01 -0.11%
After hours · Nov 20, 7:57 PM ET
8.83 Day range 9.40
4.55 52-week range 11.41
- YTD
- +53.38%
- 1 year
- +24.90%
News
seekingalpha.com Sagimet: New Acne Medication In 40 Years (Initiating With A Buy) I initiate Sagimet Biosciences at Buy with a $32 target; its roughly $370 million enterprise value undervalues a China-validated acne treatment. Denifanstat achieved 33.2% treatment success versus…
defenseworld.net Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Average Price Target of $26.07 Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat.com reports. Two…
defenseworld.net ACT Capital Partners L.P. Makes New $593,000 Investment in Sagimet Biosciences Inc. $SGMT ACT Capital Partners L.P. purchased a new position in shares of Sagimet Biosciences Inc. (NASDAQ: SGMT) in the third quarter, according to its most recent disclosure with the Securities and Exchange…
globenewswire.com Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates FOSTER CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key…
globenewswire.com Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key…
zacks.com Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…benzinga.com Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner…
globenewswire.com Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner…
seekingalpha.com Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet Sagimet Biosciences pivots denifanstat to acne, with robust Phase 3 data and a fully funded U.S. registrational trial underway. SGMT trades below cash value, presenting an asymmetric risk/reward…
defenseworld.net Applied Dna Sciences (NASDAQ:BNBX) & Sagimet Biosciences (NASDAQ:SGMT) Head to Head Comparison Sagimet Biosciences (NASDAQ: SGMT - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
zacks.com After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street…
globenewswire.com Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the…
defenseworld.net Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed as “Buy” by HC Wainwright Sagimet Biosciences (NASDAQ: SGMT - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently…
defenseworld.net Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch Sagimet Biosciences (NASDAQ: SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN,…
marketbeat.com Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN,…
globenewswire.com Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional…
seekingalpha.com Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
benzinga.com Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris.
defenseworld.net Sagimet posts 52-week denifanstat acne data What happened Sagimet Biosciences Inc. (NASDAQ: SGMT) said denifanstat produced a 57.8% treatment success rate after up to 52 weeks in patients with moderate to severe acne. The company said the…
globenewswire.com Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional…
globenewswire.com Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed…
